A new study published in the journal Science Translational Medicine has revealed a potential breakthrough in the treatment of therapy-resistant prostate cancer.
Monthly Archives: December 2020
Sisu Pharma exploits cellular stress by directly targeting the transcription factor Heat Shock Factor 1 (HSF1), the Central Regulator of the heat shock response. Our HSF1 targeting platform (HI-LiTe) is being leveraged to deliver selective HSF1 degraders for oncology and therapies for use in neurodegenerative conditions and infection, providing a unique approach to treating these devastating diseases.
© 2025 . All rights reserved. Powered by Phlox Theme Privacy Policy